Dexamethasone News and Research

RSS

SARS-CoV-2's resistance to remdesivir in vitro

A new preprint research paper posted to the bioRxiv server discusses the emergence of mutations in the SARS-CoV-2 virus, allowing it to escape the effects of the most commonly used antiviral drug, remdesivir.

14 Feb 2021

Can early use of colchicine reduce COVID-19 mortality?

The COVID-19 pandemic, caused by SARS-CoV-2, has caused well over 2.3 million deaths in a little over a year. A new meta-analysis reports the potential utility of colchicine in treating SARS-CoV-2 infection and forestalling severe and life-threatening inflammation of the lungs and other organs.

8 Feb 2021

Scientists grow small intestinal cells from human-induced pluripotent stem cells

A team of scientists from Japan have found success in growing small intestinal cells, akin to those found in the human body, from human-induced pluripotent stem cells.

8 Feb 2021

Study could help understand mechanisms of drug molecules to mitigate COVID-19 infection

As the scientific community continues researching the novel coronavirus, experts are developing new drugs and repurposing existing ones in hopes of identifying promising candidates for treating symptoms of COVID-19.

3 Feb 2021

New process separates beneficial glucocorticoids from unwanted side-effects

A collaboration led by Scripps Research has developed a way to separate the beneficial anti-inflammatory properties of a group of steroids called glucocorticoids from some of their unwanted side-effects, through an optimization process they named "ligand class analysis."

3 Feb 2021

Zinc supplementation bolsters repurposed antivirals against SARS-CoV-2

A new preprint reports the efficacy of two repurposed drugs that could be useful against SARS-CoV-2 when supplemented with zinc.

2 Feb 2021

Antiviral compound GC-376 shows efficacy against SARS-CoV-2 in vivo

Over the past months, many potential antivirals against SARS-CoV-2 have been identified as deserving further development to target several viral proteins. A new study deals with one such molecule, the viral main protease (Mpro) inhibitor GC-376, and describes its efficacy in inhibiting virus-host interaction.

2 Feb 2021

Ivermectin may not be the ‘silver bullet’ antiviral against COVID-19

A team of researchers based in Peru and the U.S. recently examined the role of the anti-parasitic drug ivermectin in treating COVID-19.

1 Feb 2021

Colchicine may have therapeutic potential against COVID-19

A new study describes the results of colchicine in mitigating the inflammatory storm associated with COVID-19, and thus preventing a percentage of severe and critical cases.

1 Feb 2021

Vitamins and other antiviral drugs may help combat COVID-19

Evidence is emerging that vitamin D - and possibly vitamins K and A - might help combat COVID-19. A new study from the University of Bristol published in the journal of the German Chemical Society Angewandte Chemie has shown how they - and other antiviral drugs - might work.

29 Jan 2021

NSAIDs dampen antibody and inflammatory responses to SARS-CoV-2 infection in mice

New research shows that non-steroidal anti-inflammatory drugs (NSAIDs) reduced both antibody and inflammatory responses to SARS-CoV-2 infection in mice. The study appears this week in the Journal of Virology, a publication of the American Society for Microbiology.

22 Jan 2021

What are the key factors and impact of interventions in England’s COVID-19 epidemic?

Researchers from Imperial College London provide a mathematical model to help understand how SARS-CoV-2, the causative pathogen of (COVID-19), spread across England in the first two waves of the epidemic, and the effect of various interventions by the government.

18 Jan 2021

Study reports promising new monoclonal antibody against SARS-CoV-2’s spike protein

An encouraging new study describes a promising new therapeutic antibody that shows potent neutralizing activity against SARS-CoV-2, the causative agent of COVID-19.

15 Jan 2021

Could fenofibrate be an effective antiviral against SARS-CoV-2?

The resurgence of COVID-19 pandemic, caused by the SARS-CoV-2, has led to renewed efforts to find effective antivirals, both newly developed or repurposed drugs. A study reports the efficacy of the cholesterol-reducing drug fenofibrate in reducing infection rates of SARS-CoV-2 in cultured cells.

13 Jan 2021

New mathematical model proposes optimal treatment strategies for COVID-19

Getting control of COVID-19 will take more than widespread vaccination; it will also require a better understanding of why the disease causes no apparent symptoms in some people but leads to rapid multi-organ failure and death in others, as well as better insight into what treatments work best and for which patients.

5 Jan 2021

COVID-19 severity could be linked to genetic variance

A new study describes some potentially important genetic factors in the host that may shape the clinical symptoms and signs of the disease.

23 Dec 2020

Community burden of COVID-19 linked to survival rates of hospitalized patients

High rates of COVID-19 in the county where a hospital is located appears to reduce survival rates among hospitalized patients with the virus, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania and at UnitedHealth Group.

22 Dec 2020

COVID-19 pandemic highlights the risk of using systemic corticosteroids

Healthcare workers in tropical and sub-tropical settings where strongyloidiasis is prevalent or caring for patients who have travelled to such areas, need to maintain a high level of awareness about the use of corticosteroids, including when this class of anti-inflammatories is given to patients suspected of infection with SARS-CoV-2.

17 Dec 2020

Azithromycin trial fails to provide evidence of benefit in COVID-19

Early on in the COVID-19 pandemic, azithromycin was regarded as being a potentially highly effective drug against the virus that causes it, SARS-CoV-2.

16 Dec 2020

Combination of baricitinib and remdesivir could benefit some COVID-19 patients

The combination of baricitinib, an anti-inflammatory drug, and remdesivir, an antiviral, reduced time to recovery for people hospitalized with COVID-19, according to clinical trial results published in the New England Journal of Medicine.

11 Dec 2020